Biotechnology News and Research

RSS

Teva Cutting 5,000 Jobs In Global Restructuring

...

10 Oct 2013

Nuvo Scores $2M Payment From Galderma For Launch Of Topical Anesthetic In Brazil

...

10 Oct 2013

J&J Innovation, Janssen, And Joslin Diabetes To Pump Up Exercise-Related Targets

...

10 Oct 2013

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

...

10 Oct 2013

Welichem Biotech announces results of substantial issuer bid

Welichem Biotech Inc. announces today the results of its substantial issuer bid, pursuant to which the Company offered to purchase for cancellation up to 23,529,411 of its issued and outstanding common shares ("Shares") at a purchase price of $0.85 per Share for an aggregate purchase price of up to $20 million (the "Offer"). The offer expired at 5:00 p.m. (Toronto time) on October 9, 2013.

10 Oct 2013

Uterine fibroids disproportionately impact African American women

A national survey has found that uterine fibroids have a disproportionate impact on African American women, causing more severe symptoms, interfering with their daily life, and causing them to miss work. These new findings are reported in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

10 Oct 2013

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.

10 Oct 2013

Thwarting Greatwall May Trigger Mitotic Collapse And Suppress Tumor Development

...

9 Oct 2013

U.S. Army Grants QR Pharma, UCLA $3M To Test TBI Treatment

...

9 Oct 2013

Active Biotech And Hutchison China Meditech Get Rewarded

...

9 Oct 2013

U.S. Research Will "Pay Dearly" For Shutdown, ASCB Warns

...

9 Oct 2013

Catalyst, Isu Abxis To Develop Hemophilia B Candidate

...

9 Oct 2013

Flumazenil reverses stress-triggered anxiety in methamphetamine dependant rats

SUNY Downstate Medical Center announced today that Sheryl Smith, PhD, professor of physiology and pharmacology, has published new findings demonstrating a reproducible pathology that may help shed light on anxiety and mood volatility in methamphetamine dependence.

9 Oct 2013

Researchers to develop effective mucosal vaccines based on cell-targeted nanoparticles

The Knut and Alice Wallenberg Foundation will give a little over SEK 16 million to the development of new, highly-efficient mucosal vaccines. The vaccines will be drinkable or given as a nasal spray. Professor Nils Lycke at MIVAC at the Sahlgrenska Academy will in cooperation with researchers at Chalmers University of Technology and Lund University, combine technologies to develop the next generation of effective mucosal vaccines based on immunomodulation and cell-targeted nanoparticles.

9 Oct 2013

Nuventra launches innovative software platform for conducting population PK analyses

Nuventra Pharma Sciences, a specialty pharmaceutical consulting firm with global reach, is pleased to announce the launch and availability of an innovative software platform called Darwin for conducting population pharmacokinetic (PK) analyses based on a genetic algorithm paradigm.

9 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy.

9 Oct 2013